VivoSeq
Psychiatry

Depressive Disorder, Major

5

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

Depressive Disorder, Major is an early-stage landscape with 5 programs across 2 companies. The most active players are Eli Lilly, Johnson & Johnson. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

22/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 3Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSPeptide120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 71% of 7 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting4 · 50%
Completed2 · 25%
Active, not recruiting1 · 13%
Not yet recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07412756·1,000 enrolled
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06559306·752 enrolled
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07573176·600 enrolled
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07227454·258 enrolled
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants With Major Depressive Disorder (MDD)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT06785012·107 enrolled
Individualized Dual-Target Repetitive Transcranial Magnetic Stimulation (rTMS) Targeting Left Inferior Parietal Lobule and Right Dorsolateral Prefrontal Cortex Functional Connectivity for Cognitive Flexibility Impairment in Major Depressive Disorder: A Randomized, Double-Blind-Controlled Trial
Not yet recruiting·SSecond Xiangya Hospital of Central South University·Preclinical·NCT07161492·105 enrolled
The Role of Individualized Functional Connectivity Targeting in Accelerated Intelligent Neuromodulation Therapy (AINT) for Depression
Completed·BBrigham and Women's Hospital·Phase 2·NCT05680727·40 enrolled
A Study to Evaluate Sleep Electroencephalogram (EEG) Features in Participants With Major Depressive Disorder (MDD)
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07258485·94 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)